- 商品介绍
- 规格参数
- 包装参数
Biochem/physiol Actions
Enalapril, the ethyl ester of enalaprilat exhibits slight pharmacological activity until it is hydrolyzed in the liver to enalaprilat. Enalaprilat, a IV form of an angiotensin-converting-enzyme inhibitor (ACE) prevents the transformation of angiotensin I to angiotensin II, a potent vasoconstrictor.
Enalaprilat is an inhibitor of angiotensin converting enzyme (ACE), antihypertensive, and a Bradykinin B1 receptor activator.
Enalaprilat is an inhibitor of angiotensin converting enzyme (ACE), antihypertensive, and a Bradykinin B1 receptor activator. Enalaprilat has nM potency versus ACE and also activates B1 receptors to release NO.
Features and Benefits
This compound is featured on the Angiotensin Receptors and Bradykinin Receptors pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
| Quality Level | 100 |
| assay | ≥98% (HPLC) |
| solubility | H2O: 14 mg/mL at 60 °C (warming for 5 minutes),DMSO: 64 mg/mL |
| originator | Merck & Co., Inc., Kenilworth, NJ, U.S. |
| storage temp. | room temp |
| SMILES string | O.O.C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N2CCC[C@H]2C(O)=O |
| InChI | 1S/C18H24N2O5.2H2O/c1-12(16(21)20-11-5-8-15(20)18(24)25)19-14(17(22)23)10-9-13-6-3-2-4-7-13;;/h2-4,6-7,12,14-15,19H,5,8-11H2,1H3,(H,22,23)(H,24,25);2*1H2/t12-,14-,15-;;/m0../s1 |
| InChI key | MZYVOFLIPYDBGD-MLZQUWKJSA-N |
| Gene Information | human ... ACE(1636) |
| 长度(mm) | |
| 宽度(mm) | |
| 高度(mm) | |
| 重量(kg) |
-
询价
-
询价
-
询价
-
¥ 1866.29
-
¥ 4173.75
-
¥ 8293.41
-
询价
-
¥ 8520.40
-
询价
-
询价
-
¥ 4404.38
-
¥ 1156.91
-
¥ 5061.38
-
¥ 3404.94
-
¥ 1351.48
-
¥ 56581.65
-
询价
-
¥ 17652.29
-
¥ 3704.60
-
¥ 200318.99
微信小程序
7X24小时在线咨询